Page 8 - Demo
P. 8
IN THE SPOTLIGHT: CONTINUED ANDY OFFREDA
Pearls you can share to generate dialogue with our new resources
ASCVD mini flow- creating urgency and opportunity to address the residual risk for patients w/T2D and ASCVD. Specifically...separate studies (non-branded slide) pointing out "ASCVD was the most prevalent CV complication among T2D patients" and "People with T2D have a 2-4X HIGHER Risk of Stroke or MI vs those without T2D", and statement of support (non-branded slide) from major medical societies and use of GLP-1 RA's with proven CVD benefit. With the awareness and after I pause, as I make your way to then tell the story about Ozempic (SUSTAIN 6), healthcare professionals really appreciate the value of a 26% RRR of MACE on the composite primary endpoint when added to standard of care.
